Christoph Rader
Chief Technology Officer Aethon Therapeutics
Seminars
Thursday 11th September 2025
Companion T Cell Engagers for Covalent Inhibitors of Oncoproteins Blend Targeted & Immune Therapy to Overcome Cancer Cell Resistance
11:00 am
- Exploring how the lack of durability of targeted therapy with covalent inhibitors of oncoproteins can be addressed with immune therapy – Looking at how MHC presentation of the covalently modified oncoprotein peptides on the cancer cell surface creates synthetic neoantigens (p*MHC) that can be targeted by antibodies with picomolar affinity and cross-HLA specificity
- Converting to p*MHC × CD3 T cell engagers to create a unique combination of targeted and immune therapy with the potential to impede cancer cell resistance
- Assessing preclinical proof-of-concept studies based on covalent inhibitors of oncoprotein KRAS G12C
